Viscogliosi Brothers Acquisition Corp. Prices of $75 Million IPO

Viscogliosi Brothers Acquisition Corp. announced today that it priced its initial public offering of 7,500,000 units at $10.00 per unit. The units are expected to be listed on The NASDAQ Global Market and trade under the ticker symbol “VBOCU” beginning January 7, 2022. Each unit consists of one share of common stock, par value $0.0001, and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one share of common stock at a price of $11.50 per whole share, subject to adjustment. Once the securities comprising the units begin separate trading, the common stock and warrants are expected to be listed on NASDAQ under the symbols “VBOC” and “VBOCW”, respectively.

Raymond James & Associates, Inc. acted as sole book-running manager for the offering. The underwriters have been granted a 45-day option to purchase up to an additional 1,125,000 units to cover over-allotments, if any. The offering is expected to close on January 11, 2022, subject to customary closing conditions.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Viscogliosi Brothers Acquisition Corp.
Viscogliosi Brothers Acquisition Corp. is a blank check company incorporated in Delaware whose business purpose is to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. Viscogliosi Brothers Acquisition Corp.’s best efforts to identify a prospective target business will not be limited to a particular industry or geographic region for purposes of consummating an initial business combination, although the Company intends to focus on businesses that have their primary operations located in North America and Europe in the neuro-musculoskeletal industry.